Antibody–Drug Conjugates in Non–Small Cell Lung Cancer: Where Are the Target and the Biomarker? Available to Purchase

Antibody–drug conjugates are an emerging treatment of non–small cell lung cancer. Some do not require biomarkers, whereas others require mutations and/or protein expression. New diagnostic technologies give opportunities for better target identification and selection of patients. Combination therapies might broaden relevant patient populations but might call for combined biomarker selection paradigms.

See related article by Trontzas et al., p. 2767